Lifevantage Corp
For the period ended Jun 30, 2024. Filed Aug 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Aug 28, 2024
LFVN$4.56-13.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The following documents are being filed as part of this report:
Financial Statements
(a)(1) Financial Statements. The following consolidated financial statements of LifeVantage Corporation and Report of Independent Registered Public Accounting Firm are included in a separate section of this Annual Report on Form 10-K.
(a)(2) All schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions or are inapplicable, or because the required information is included in the financial statements or notes thereto, and therefore have been omitted.
Exhibits
(a)(3) The following exhibits are filed as part of, or incorporated by reference into, the Annual Report on Form 10-K.
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 3.1 | Certificate of Incorporation | Exhibit 3.1 to Form 8-K filed on March 13, 2018. |
| 3.2 | Amended and Restated Bylaws | Exhibit 3.1 to Form 8-K filed on August 15, 2019. |
| 3.3 | Certificate of Designation of Series A Junior Participating Preferred Stock of the Company | Exhibit 3.1 to Form 8-K filed on August 31, 2023. |
| 4.1 | Form of Common Stock Certificate | Exhibit 4.1 to Form 8-K filed on March 13, 2018. |
| 4.3 | Rights Agreement, dated as of August 30, 2023, by and between the Company and Computershare Trust Company, N.A., as Rights Agent | Exhibit 4.1 to Form 8-K filed on August 31, 2023. |
| 10.1 | Cooperation Agreement, dated February 14, 2024, by and among the Company, the entities and persons listed on Exhibit A thereto, and the entities and persons listed on Exhibit B thereto | Exhibit 10.1 to Form 8-K filed on February 15, 2024. |
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 10.2.4# | Evolve Compensation Plan (Japan) in US/English Format | Exhibit 10.1.4 to Form 10-K filed on August 28, 2023. |
| 10.2.5# | Evolve Compensation Plan (Canada) | Exhibit 10.5 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024. |
| 10.2.6# | Evolve Compensation Plan (Mexico) | Exhibit 10.6 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024. |
| 10.2.7# | Evolve Compensation Plan (UK) | Exhibit 10.7 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024. |
| 10.2.8# | Evolve Compensation Plan (EU) | Exhibit 10.8 to Form 10-Q filed for the fiscal quarter ended March 31, 2024 filed on May 2, 2024. |
| 10.3# | Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan | Filed herewith. |
| 10.4# | Form of Restricted Stock Grant Agreement for the 2017 Long-Term Incentive Plan | Exhibit 99.2 to the Registration Statement on Form S-8 filed on March 27, 2017. |
| 10.5# | Form of Stock Unit Agreement for the 2017 Long-Term Incentive Plan | Exhibit 99.3 to the Registration Statement on Form S-8 filed on March 27, 2017. |
| 10.6# | LifeVantage Corporation 2019 Employee Stock Purchase Plan | Exhibit 10.2 to Form 8-K filed on November 19, 2018. |
| 10.7 | Form of Indemnification Agreement | Exhibit to 99.1 to Form 8-K filed on March 13, 2018. |
| 10.8# | CEO Offer Letter, dated January 31, 2021, by and between the Company and Steven R. Fife | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed on April 29, 2021. |
| 10.9# | Form of Key Executive Benefits Agreement | Filed herewith. |
| 10.10 | Loan Agreement, dated April 12, 2024, by and between the Company and Bank of America, N.A. | Exhibit 10.1 to Form 8-K filed on April 16, 2024. |
| 10.11 | Continuing and Unconditional Guaranty, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A. | Exhibit 10.2 to Form 8-K filed on April 16, 2024. |
| 10.12 | Security and Pledge Agreement, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A. | Exhibit 10.3 to Form 8-K filed on April 16, 2024. |
| 10.13 | Loan Agreement, dated March 30, 2016, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.1 to Form 8-K filed on April 4, 2016. |
| 10.14 | Security Agreement, dated March 30, 2016, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.2 to Form 8-K filed on April 4, 2016. |
| 10.15 | Amended No.1 to Loan Agreement, dated May 4, 2018, by and between Z.B., N.A., the Company and Lifeline Nutraceuticals Corporation | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended March 31, 2018 filed on May 9, 2018. |
| 10.16 | Second Loan Modification Agreement, dated February 1, 2019, by and between Zions Bank and the Company | Exhibit 10.1 to Form 8-K filed on February 4, 2019. |
| ExhibitNo. | Document Description | Filed Herewith or Incorporated by Reference From |
| 10.17 | Change in Terms Agreement, dated April 1, 2021, by and between Zions Bank and the Company | Exhibit 10.3 to Form 10-Q filed for the fiscal quarter ended March 31, 2021 filed on April 29, 2021. |
| 10.18 | Change in Terms Agreement, dated September 30, 2022 by and between the Company and Zions Bank | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2022 filed on November 2, 2022. |
| 10.19 | Lease Agreement, dated November 14, 2019, by and between Traverse Ridge Center III and the Company | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended December 31, 2019 on January 28, 2020. |
| 10.20 | Lease Agreement, dated May 26, 2023, by and between Sumitomo Mitsui Trust Bank, Limited and LifeVantage Japan in US/English Format | Exhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2023 filed on November 9, 2023. |
| 10.21* | Commercial Supply Agreement, dated January 31, 2014, by and between the Company and Deseret Laboratories, Inc. | Exhibit 10.1 to Form 10-Q for the fiscal quarter ended March 31, 2014 filed on May 6, 2014. |
| 10.22* | Service Agreement, dated June 1, 2014, by and between IntegraCore, LLC and the Company | Exhibit 10.29 to Form 10-K for the fiscal year ended June 30, 2014 filed on September 10, 2014. |
| 10.23* | Commercial Supply Agreement, dated May 30, 2014, by and between the Company and Wasatch Product Development | Exhibit 10.30 to Form 10-K for the fiscal year ended June 30, 2014 filed on September 10, 2014. |
| 21.1 | List of Subsidiaries | Filed herewith. |
| 23.1 | Consent of Deloitte & Touche, LLP | Filed herewith. |
| 24.1 | Power of Attorney | Signature page to this report. |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith. |
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | Filed herewith. |
| 32.1 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith. |
| 32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | Furnished herewith. |
| 97.1 | Company Policy for the Recovery of Erroneously Awarded Compensation (Clawback Policy) | Filed herewith. |
| 101 | The following financial information from the registrant’s Annual Report on Form 10-K for the year ended June 30, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Other Comprehensive Income; (iii) Consolidated Statement of Stockholders’ Deficit; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements, tagged as blocks of text. | Filed herewith. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | Filed herewith. |
| # | Management contract or compensatory plan. |
|---|---|
| * | The company has been granted confidential treatment for portions of this agreement. Accordingly, certain portions of this agreement have been omitted in the version filed with this report and such confidential portions have been filed with the SEC. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.